A coronary sinus reducer met one of two primary endpoints by reducing refractory angina in the ORBITA-COSMIC trial, but not the second, improvement in perfusion.
Intranasal oxytocin appears to improve social functioning and quality of life in individuals with autism spectrum disorder, results of a randomized control trial show.
Phase 4 involves initiating therapy, which includes demonstrating empathy by reflecting on the detrimental effects of the patient's reported sensations on their quality of life.